Twin Peaks Launches Year’s First IPO
Sports bar chain Twin Peaks starts trading Thursday on the NASDAQ using the ticker “TWNP,” making it the first restaurant initial public offering of the new year and a potential litmus test for others looking to go public.The IPO market has been tepid for several years, particularly for consumer companies. Soaring inflation, higher interest rates, cautious consumers and the risk of lower valuations scared many companies away from going public. Market conditions meant that some companies chose to seek a sale rather than trying their luck with the public markets. Even the rare success, like Cava’s IPO, didn’t convince others to follow its path.But many are hopeful that the IPO market will thaw this year.“Last year was a stronger year than 2023, and we’re expecting 2025 to have more IPOs than 2024,” said Nick Einhorn, vice president of research for Renaissance Capital, a provider of pre-IPO research and IPO-focused ETFs. “That could certainly include more consumer IPOs.”Twin Peaks won’t be the first consumer company to make the leap this year — and that debut may not inspire confidence.Pork producer Smithfield Foods, a subsidiary of Hong Kong-based WH Group, began trading on Tuesday. Shares fell 7% from its IPO price of $20 during its market debut. The company had already downsized its offering by 8.1 million shares and priced below its marketed range. Smithfield’s challenges include its ties to China, U.S. trade tensions with Mexico and proposed immigration policies that would raise its labor costs.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


